GlassScriptPhysician profile
Paul M Volansky
NPI 1588006043
$14,884.37
in general payments reported to CMS, 2019-2025
47 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,813 · 2020: $471 · 2021: $1,627 · 2022: $1,923 · 2023: $3,916 · 2024: $2,749 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,160 · Travel and Lodging: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,160.45 |
| Travel and Lodging | $1,890.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,783.11 | 2019-2025 | Impella |
| Boston Scientific Corporation | $1,700.03 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Rotablator Rotational Atherectomy System Console Kit, General - Stents |
| Medtronic, INC. | $1,317.66 | 2022-2025 | Turbohawk, Onyx Frontier, Symplicity G3 |
| Biotronik INC. | $1,271.90 | 2019-2025 | Amvia Edge, Orsiro Mission, Rivacor 7 Dr-T |
| Penumbra, INC. | $909.29 | 2022-2025 | Indigo System, Penumbra System, Smart Coil |
| Astrazeneca Pharmaceuticals LP | $834.61 | 2019-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $566.26 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $553.67 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.05 | 2021-2025 | Jardiance, Ofev |
| Pfizer INC. | $498.88 | 2020-2025 | |
| United Therapeutics Corporation | $363.29 | 2023-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $356.99 | 2024-2025 | Smartvest |
| Grifols USA, LLC | $354.53 | 2022-2025 | Prolastin-C Liquid |
| Cvrx, INC. | $296.14 | 2023-2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $287.41 | 2021-2025 | Camzyos, Eliquis |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $254.00 | 2020-2025 | Repatha, Repatha |
| Chiesi USA, INC. | $231.62 | 2019-2025 | Kengreal, Cleviprex |
| Merck Sharp & Dohme LLC | $201.71 | 2021-2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $188.61 | 2019-2024 | |
| Esperion Therapeutics, INC. | $178.79 | 2024-2025 | Nexletol, Nexlizet |
| Angiodynamics, INC. | $167.86 | 2022-2025 | Auryon Laser System 100-120 Vac |
| Daxor Corporation | $99.70 | 2022-2023 | Bva-100 |
| Novo Nordisk INC | $95.25 | 2024-2025 | Wegovy |
| Avinger INC. | $82.74 | 2022 | |
| Abbott Laboratories | $81.21 | 2021-2022 | |
| Daiichi Sankyo INC. | $62.86 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $62.21 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $60.21 | 2019-2020 | |
| Astellas Pharma US INC | $55.67 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $50.00 | 2024-2025 | |
| Resmed Corp | $44.40 | 2024-2025 | |
| Cardiva Medical, INC. | $38.97 | 2023-2024 | Cardiva Vascade 6/7f Vcs |
| Regeneron Healthcare Solutions, INC. | $35.26 | 2019 | |
| Philips North America LLC | $31.29 | 2022-2024 | (Ak6) Vest Therapy |
| Glaxosmithkline, LLC. | $28.94 | 2025 | Arexvy, Shingrix |
| Portola Pharmaceuticals, LLC | $26.37 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.84 | 2025 | Amvuttra |
| Braemar Manufacturing, LLC | $22.75 | 2019 | |
| Convatec INC. | $20.15 | 2019 | |
| Bridgebio Pharma, INC. | $19.97 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $18.94 | 2020 | |
| Harmony Biosciences LLC | $18.62 | 2023 | Wakix |
| Nuwellis, INC. | $18.56 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.43 | 2022 | |
| Csl Behring | $16.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2022 | |
| Terumo Medical Corporation | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Volansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.